A Randomized, Open-Label, Phase II Study of Canakinumab or Pembrolizumab As Monotherapy or in Combination as Neoadjuvant Therapy in Subjects with Resectable Non-Small Cell Lung Cancer CANOPY-N
A Randomized Phase III Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy
Phase II Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligometastatic Non-Small Cell Lung Cancer and Renal Cell Carcinoma
EA5163/S1709 INSIGNA : A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer NSCLC with Immunobiomarker SIGNature-Driven Analysis
Prospective Registrational Trial to Define Real World Outcomes of Patients with Completely Resected Stage I or IIA Non-squamous Non-Small Cell Lung Cancer NSCLC Identified as High, Intermediate, or Low Risk by a 14-Gene Prognostic Assay, DetermaRXTM, being Considered for Adjuvant Platinum-based chemotherapy or other Adjuvant therapy versus Observation